<DOC>
	<DOC>NCT01676688</DOC>
	<brief_summary>The purpose of this study is to collect safety data on ALFALASTIN® infusions performed at home or in out-of hospital locations.</brief_summary>
	<brief_title>Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home</brief_title>
	<detailed_description>Non interventional, observational, longitudinal, prospective, multicenter, non comparative study.</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Participation Criteria: Patients above 18 y.o, suffering from severe forms of primary alpha1 antitrypsin deficiency, phenotype PiZZ or PiSZ with pulmonary emphysema, currently treated as per routine practice, once a week, by ALFALASTIN® at home or in outofhospital location and having signed informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>alpha-1 antitrypsin</keyword>
	<keyword>deficiency</keyword>
	<keyword>Alfalastin</keyword>
	<keyword>safety</keyword>
</DOC>